Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 17Thymosin Alpha-1 literaturePubMed · Observational2025

Thymosin α1 alleviates pulpitis by inhibiting ferroptosis of dental pulp cells.

Thymosin α1 may influence inflammatory responses in pulpitis by inhibiting ferroptosis in dental pulp cells, but further research is needed to confirm these effects in humans.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the thymosin alpha-1 corpus
2
Preclinical
12
Observational · this one
0
Open-label
2
Randomised
1
Reviews

Summary and findings

This study investigated the role of thymosin α1 in alleviating pulpitis by inhibiting ferroptosis in dental pulp cells. The research utilized single-cell RNA sequencing to analyze 40,231 cells from pulpitis and healthy tissue. Key findings indicated changes in gene expression and inflammatory markers in response to thymosin α1 treatment.

How much of this paper we could read: partial text (0.60). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2025

Abstract

The authors’ words, as PubMed supplied them

Tooth pulpitis is a prevalent oral disorder. Understanding the underlying mechanisms of pulpitis and developing effective treatment strategies hold great significance. Ferroptosis has recently emerged as a new form of cell death, but the role of ferroptosis in pulpitis remains largely unknown. In our study, single-cell RNA sequencing (scRNA-seq) was used to identify cellular heterogeneity between 3 pulpitis tissue and 3 healthy pulp tissue, and explored ferroptosis occurrence in pulpitis tissue and inflamed dental pulp cells (DPCs). In scRNA-seq, 40 231 cells (Pulpitis: 17 814; Healthy pulp: 22 417) were captured, and visualized into 12 distinct cell clusters. Differentially expressed ferroptosis-related genes (DE-FRGs) were almost presented in each cluster in pulpitis vs healthy pulp. ROS and Fe<sup>2+</sup> levels significantly rose, and immunohistochemistry showed low expression of GPX4 and high expression of PTGS2 in pulpitis. In LPS-stimulated DPCs, thymosin α1 increased the expression of GPX4 and FTL, and decreased expression of TNF-α, IL-1β, IL-6, and Fe<sup>2+</sup> levels. In rat pulpitis models, both prothymosin α (PTMA, precursor of thymosin α1) gelatin sponge placed at the hole of pulp (LPS-P(gs)) and PTMA injection in pulp (LPS-P(i)) significantly reduced infiltration of inflammatory cells and expression of PTGS2, and increased the expression of GPX4. In RNA sequencing, the expression of DE-FRGs were reversed when thymosin α1 were added in LPS-stimulated DPCs. Collectively, single-cell atlas reveals cellular heterogeneity between pulpitis and healthy pulp, and ferroptosis occurrence in pulpitis. Thymosin α1 may reduce ferroptosis in DPCs to alleviate pulpitis and thus potentially has the ability to treat pulpitis.

Background

The study addresses the biological question of how Thymosin Alpha-1 may impact pulpitis, a condition characterized by inflammation of the dental pulp. Prior research has suggested that ferroptosis, a form of regulated cell death, may play a role in the pathology of pulpitis. Understanding the mechanisms by which Thymosin Alpha-1 operates could provide insights into potential therapeutic strategies.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the Thymosin Alpha-1 corpus

BThymosin α1-induced secretion of the IL-15/RA complex by THP-1-derived dendritic cells restrains HIV latency in vitro.Virulence · 2026 · Intracellular p24 levels in CD4+ T cells decreased significantly, p=0.002.HumanDReply to 'F508del-CFTR is not corrected by thymosin α1'.Nature medicine · 2018BF508del-CFTR is not corrected by thymosin α1.Nature medicine · 2018In vitroAThe efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025 · 28-day all-cause mortality: 23.4% (127/542) in thymosin α1 group vs 24.1% (132/547) in placebo group, hazard ratio 0.99, 95% CI 0.77 to 1.27, P=0.93.HumanBProximal tubule reabsorptive dysfunction and risk of cardiovascular death among community-living adults: the HUNT-3 cohort.europepmc · 2026 · 1-SD higher urine A1M associated with HR 1.33 (95% CI 1.12-1.58) for cardiovascular death.HumanBPrecision biomarker discovery in hypertension through explainable AI and proteomics.europepmc · 2026 · AUROC = 0.7985 for CatBoost classifier.Human